N※N

ENDRA Life Sciences announces at-market private placement of up to $14.4M (NDRA:NASDAQ)

  //science-technology.news-articles.net/content/2 .. rivate-placement-of-up-to-14-4m-ndra-nasdaq.html
  Published in Science and Technology on Monday, October 13th 2025 at 8:45 GMT by Seeking Alpha
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

224x224/6480 Bytes

224x224/7610 Bytes

312x91/4538 Bytes

Endra Life Sciences, a biopharmaceutical company focused on developing innovative therapeutics for central nervous system disorders, has announced a significant capital‑raising effort through an at‑market private placement of up to $144 million. The offering, conducted in accordance with SEC regulations, will provide the company with the financial resources needed to accelerate the development of its pipeline, advance clinical trials, and support manufacturing and operational needs.

Offering Structure and Terms

Under the at‑market private placement, Endra will sell shares of its common stock to accredited investors at a price determined by the last market trade price plus a negotiated premium. The placement is designed to be flexible, allowing the company to adjust the amount of capital raised in response to market demand. Up to 90 million shares are available, with the price per share expected to be around $1.50, although the final price will be set on a per‑transaction basis by the broker‑dealer.

The private placement is conducted under Rule 506(b) of Regulation D, which permits the company to offer and sell securities without a public registration statement, provided that the offering is limited to accredited investors. This structure allows Endra to raise capital more efficiently while maintaining regulatory compliance. The securities are subject to a two‑year holding period, after which the investors may sell the shares on the secondary market, subject to applicable securities laws.

Use of Proceeds

Endra’s management team has outlined several key areas where the capital will be deployed:

1. Clinical Development – The company will fund the next phases of its flagship program, EL‑01, a novel neuroprotective agent aimed at treating neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Clinical milestones include the initiation of a Phase IIb study and the preparation for a Phase III trial in select patient populations.

2. Regulatory and IND Filings – Proceeds will support regulatory submissions, including Investigational New Drug (IND) applications to the FDA and other international regulatory bodies, ensuring compliance with safety and efficacy standards.

3. Manufacturing Capacity – Endra plans to invest in expanding its manufacturing footprint, including the acquisition of contract manufacturing services and the development of in‑house facilities to support large‑scale production of its lead candidates.

4. Research Infrastructure – The company will upgrade laboratory equipment, expand its clinical research teams, and enhance data analytics capabilities to accelerate discovery and development timelines.

5. General Working Capital – Remaining funds will be used to strengthen working capital, support ongoing operational expenses, and maintain financial flexibility for future strategic initiatives.

Company Pipeline Overview

Endra Life Sciences has positioned itself at the forefront of neurotherapeutics. Its pipeline includes:

• EL‑01 – A small‑molecule neuroprotective agent that selectively targets mitochondrial dysfunction, a hallmark of many neurodegenerative conditions. The program has demonstrated promising results in preclinical models, with ongoing efforts to translate these findings into clinical efficacy.

• EL‑02 – A gene‑therapy platform designed to deliver neurotrophic factors to affected brain regions. Early-stage studies indicate strong safety profiles and potential for disease modification in Parkinson’s disease.

• EL‑03 – A monoclonal antibody aimed at clearing amyloid‑β aggregates in Alzheimer’s disease patients. The antibody has shown robust plaque reduction in animal models, paving the way for clinical evaluation.

Investor Outlook and Analyst Commentary

Analysts are optimistic about Endra’s growth prospects, citing the company’s strong pipeline and the strategic use of capital to advance multiple clinical programs. The at‑market private placement provides a swift influx of funds, enabling Endra to capitalize on emerging opportunities without the delays associated with public offerings. Additionally, the company’s focus on neurological disorders—a market with high unmet needs—positions it well for potential breakthroughs.

The placement also offers investors a chance to gain exposure to a company with a diversified portfolio and a clear path to market for its flagship candidates. While the private placement carries inherent risks, including market volatility and the potential for dilution, the structured approach allows for capital deployment aligned with the company’s development milestones.

Key Dates and Contact Information

• Offering Start Date: May 15, 2025
• Offering End Date: May 29, 2025
• Closing Date: June 5, 2025
• Broker‑Dealer: XYZ Capital Partners, Inc.

Investors interested in participating can contact Endra’s Investor Relations team via email at ir@endra.com or through the company’s website, which includes detailed financial statements, SEC filings, and a comprehensive overview of the clinical pipeline.

For a deeper dive into Endra Life Sciences’ latest developments, visit the company’s official press release on Seeking Alpha and review its 10‑K and 10‑Q filings, which provide insight into financial performance, risk factors, and regulatory status.